Immutep Limited
Immutep Limited (IMMP) Revenue
Annual & quarterly revenue history · segment & region breakdown
IMMP · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsImmutep Limited trailing twelve-month (TTM) revenue is $0.01B, an increase of 31.28% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2008 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-06-30 | $0.01B | +$0.00B | +31.28% |
| 2024-06-30 | $0.00B | +$0.00B | +9.59% |
| 2023-06-30 | $0.00B | +$0.00B | +1957.72% |
| 2022-06-30 | $0.00B | -$0.00B | -95.59% |
| 2021-06-30 | $0.00B | -$0.00B | -48.40% |
| 2020-06-30 | $0.01B | +$0.01B | +5255.80% |
| 2019-06-30 | $0.00B | -$0.00B | -94.69% |
| 2018-06-30 | $0.00B | -$0.00B | -37.69% |
| 2017-06-30 | $0.00B | +$0.00B | +2311.59% |
| 2016-06-30 | $0.00B | -$0.00B | -91.64% |
Compare revenue vs peers
BiotechnologyCompare IMMP revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Immutep Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Immutep Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in AUD.
Data sourced from Immutep Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IMMP revenue · 4 questionsIMMP's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 31.28% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Immutep Limited SEC filings · GAAP · Immutep Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026